ASH 2025 preview – a new menin battleground
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
J&J catches its menin rivals
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
